Here's what the grant actually represents: not a new discovery so much as the continued extension of a foundational estate that much of the gene-editing industry has to reckon with.

Strip away the decade-old drama about who invented CRISPR first, and the practical reality is simpler. The Broad Institute holds a deep set of patents on the core editing enzymes and systems. Its 2022 grant US11352647B2 on CRISPR enzymes and systems is one more brick in that wall.

“Embodiments disclosed herein are directed to engineered CRISPR-Cas effector proteins that comprise at least one modification compared to an unmodified CRISPR-Cas effector protein that enhances binding of the of the CRISPR complex to the binding site and/or alters editing preference as compared to wi…”— U.S. Patent No. 11,352,647 source

Why does a single grant to one institute ripple outward? Because gene-editing therapies are built on these enzymes. A company developing a CRISPR treatment for a disease often finds that the basic machinery it depends on touches foundational claims — which means licensing, or designing around them.

You can see the design-around pressure in the same year's filings. Rutgers' US11390886B2 describes a nuclease-independent editing platform — an approach that deliberately steps off the most heavily claimed ground. Inventors don't pursue alternatives in a vacuum; they do it partly to find freedom to operate.

The crosswalk worth keeping: a foundational patent isn't just a credit line on a discovery — it's a tollbooth on a road the whole field drives. When the Broad issues another core grant, it's reinforcing that tollbooth, and that's a commercial fact every gene-editing company has to plan around.

None of this resolves who 'deserves' the credit, and a pending or issued claim isn't the last word in a contested area. But for a reader trying to understand why CRISPR economics are so tangled, the answer starts here: the foundational estate is active, broad, and still growing.